Hypertonic Saline for Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease

Brief description of study

The purpose of this study is to learn more about whether nebulized hypertonic saline can help improve symptoms and clearance of mycobacteria. Hypertonic saline (7% solution) for inhalation is sometimes prescribed to patients with Mycobacterium Avium Complex(MAC) lung infections. The researchers also want to learn how much of a burden this treatment is for participants with MAC. Hypertonic saline (7%) will be called the “study drug” throughout this form. The use of the hypertonic saline (7%) for pulmonary NTM has not been approved by the Food and Drug Administration (FDA) because we do not know enough about it. Therefore, in this study, its use is considered investigational. Hypertonic saline has been used in those with other lung problems(bronchiectasis, cystic fibrosis), but has not been studied in those with MAC lung infections.


Clinical Study Identifier: s21-00922
ClinicalTrials.gov Identifier: NCT04921943


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.